

Name of the issue: Glenmark Life Sciences Limited

1 **Type of issue (IPO/ FPO)** IPO

2 **Issue size (Rs. in crore)** 1,513.60

Source: Prospectus dated July 30, 2021

3 **Grade of issue alongwith name of the rating agency**

Name Not Applicable
Grade Not Applicable

4 **Subscription Level (Number of times)** 43.73*

*Excluding Anchor Investor Portion and after removing multiple and duplicate bids and technical rejections cases from Basis of allotment dated August 3, 2021

5 **QIB holding (as a %age of total outstanding capital) as disclosed to stock exchanges**

Particulars	%
(i) On Allotment Aug 3, 2021 ⁽¹⁾	8.58%
(ii) at the end of the 1st Quarter immediately after the listing (Sep 30, 2021)	8.49%
(iii) at the end of 1st FY (March 31, 2022)	8.68%
(iv) at the end of 2nd FY (March 31, 2023) ⁽²⁾	Not available
(v) at the end of 3rd FY (March 31, 2024) ⁽²⁾	Not available

(1) Source: Basis of Allotment. Includes allotment to Anchor Investors

(2) QIB Holding not disclosed as reporting for relevant period has not been completed.

6 **Financials of the issuer**

(Consolidated Rs. in crore)

Parameters	1st FY (March 31,2022)	2nd FY (March 31,2023) *	3rd FY (March 31,2024) *
Income from operations	2123.21	Not Available	Not Available
Net Profit for the period	418.72	Not Available	Not Available
Paid-up equity share capital	24.5	Not Available	Not Available
Reserves excluding revaluation reserves	2029.81	Not Available	Not Available

Note: *Financials for the year ended March 31, 2023 and March 31, 2024 shall be updated in due course

7 **Trading status in the scrip of the issuer**

Company's Equity Shares are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE")

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2023) ⁽¹⁾	Not Available
(iii) at the end of 3rd FY (March 31, 2024) ⁽¹⁾	Not Available

⁽¹⁾ will be updated in due course

8 Change, if any, in directors of issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
at the end of 1st FY March 31, 2022	NIL	
at the end of 2nd FY March 31, 2023 ⁽¹⁾	Not Available	
at the end of 3rd FY March 31, 2024 ⁽¹⁾	Not Available	

(1) Information shall be updated in due course

9 Status of implementation of project/ commencement of commercial production

Particulars	Remarks
(i) as disclosed in the offer document	
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	

10 Status of utilization of issue proceeds (INR cr)

(i) as disclosed in the offer document

Particulars	Amount (Rs. million)
Payment of outstanding purchase consideration to the Promoter for the spin-off of the API business from the Promoter	8,000.0
Funding the capital expenditure requirements	1,527.6
General corporate purposes	576.8
Total	10,104.4

(ii) Actual utilization

Particulars	Amount (Rs. million)
Payment of outstanding purchase consideration to the Promoter for the spin-off of the API business from the Promoter	8,000.0
Funding the capital expenditure requirements	762.1
General corporate purposes	494.4
Total	9,256.5

(iii) Reasons for deviation, if any

Not Available

11 Comments of monitoring agency, if applicable - N/A

- (a) Comments on use of funds Utilized as per disclosure in offer document
 (b) Comments on deviation, if any, in the use of proceeds of the issue from the ob NA
 (c) Any other reservations expressed by the monitoring agency about the end use -

12 Price-related data

Designated SE BSE
 Issue Price (Rs.) 720
 Listing Date August 6, 2021

Price parameters	As at the end of March 31, 2022					
	At close of listing day August 6, 2021	At close of 30th calendar day from listing day September 4, 2021	At close of 90th calendar day from listing day November 04, 2021			
Market Price	748.20	674.05	630.90			
BSE Sensex	54,277.72	58,129.95	60,067.62			
Sectoral Index (S&P BSE Healthcare)	26,369.65	26,754.78	25,316.33			
As at the end of March 31, 2022	Closing price	High	Low			
Market Price	459.00	799.95	376.00			
BSE Sensex	58,568.51	62,245.43	47,204.50			
Sectoral Index (S&P BSE Healthcare)	24,303.83	26,979.05	21,236.14			
Price parameters	As at the end of March 31, 2023 ⁽¹⁾			As at the end of March 31, 2024 ⁽¹⁾		
	Closing price	High	Low	Closing price	High	Low
Market Price	-	-	-	-	-	-
BSE Sensex	-	-	-	-	-	-
Sectoral Index (S&P BSE Healthcare)	-	-	-	-	-	-

Source: Stock Exchange data. Where the 30th day / 90th day / March 31 of a particular year falls on a holiday, the immediately preceding trading day has been considered

(1) will be updated in due course

1. Market price on BSE taken, being the designated stock exchange

2. High and Low based on closing prices

13 Basis for Issue Price and Comparison with Peer Group & Industry Average

Accounting ratio	Name of company	As disclosed in the offer document (1)	At the end of 1st FY March 31, 2022	At the end of 2nd FY March 31, 2023 (2)	At the end of 3rd FY March 31, 2024 (2)
EPS (Basic)	Issuer: Consolidated	32.61	36.63	Not Available	Not Available
	Peer Group:				
	Divis Laboratories Limited	74.75	111.52	Not Available	Not Available
	Laurus Labs Limited	18.36	15.42	Not Available	Not Available
	Shilpa Medicare Limited	18.13	7.26	Not Available	Not Available
	Aarti Drugs Limited	30.09	22.12	Not Available	Not Available
	Solara Active Pharma Sciences Limited	69.00	-16.18	Not Available	Not Available
	Industry Avg	42.07	28.03	Not Available	Not Available
	Issuer: Consolidated	22.08	12.53	Not Available	Not Available
	Peer Group:				
Divis Laboratories Limited	63.65	39.49	Not Available	Not Available	
Laurus Labs Limited	36.59	38.44	Not Available	Not Available	
Shilpa Medicare Limited	33.37	54.7	Not Available	Not Available	
Aarti Drugs Limited	24.28	19.39	Not Available	Not Available	
Solara Active Pharma Sciences Limited	25.83	-16.18	Not Available	Not Available	
Industry Avg	36.74	25.34	Not Available	Not Available	
RoNW%	Issuer: Consolidated	46.71%	20.38%	Not Available	Not Available
	Peer Group:				
	Divis Laboratories Limited	21.35%	25.24%	Not Available	Not Available
	Laurus Labs Limited	37.87%	24.83%	Not Available	Not Available
	Shilpa Medicare Limited	9.99%	3.32%	Not Available	Not Available
	Aarti Drugs Limited	30.70%	19.78%	Not Available	Not Available
	Solara Active Pharma Sciences Limited	13.93%	-3.82%	Not Available	Not Available
Industry Avg:	22.77%	13.87%	Not Available	Not Available	
NAV per share	Issuer: Consolidated	69.82	167.66	Not Available	Not Available
	Peer Group:				
	Divis Laboratories Limited	350.12	441.79	Not Available	Not Available
	Laurus Labs Limited	48.41	62.36	Not Available	Not Available
	Shilpa Medicare Limited	181.37	209.93	Not Available	Not Available
	Aarti Drugs Limited	98.01	111.92	Not Available	Not Available
	Solara Active Pharma Sciences Limited	442.12	423.63	Not Available	Not Available
	Industry Avg:	224.01	249.93	Not Available	Not Available

(1) Sourced from Prospectus dated July 30, 2021

(2) Information not provided as the relevant fiscal year has not completed / not disclosed in public domain

14 Any other material information

Particulars	Date
Board of Directors of the Company at its meeting held on April 20, 2022, inter alia, has recommended final Dividend of Rs. 10.50 per share (face value of Rs. 2/- each) on the Equity Share Capital of the Company for the financial year 2021 - 22	4/21/2022
Mr. Bhavesh Pujara has resigned as the Chief Financial Officer of the Company with effect from the close of business hours on April 22, 2022. Appointment of Mr. Tushar P. Mistry as the Chief Financial Officer (designated as Key Managerial Personnel) of the Company with effect from June 1, 2022.	4/20/2022

Source- Stock Exchange filings

For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com